Other Events ·
Novartis announced that the FORTITUDE Phase I/II study of delpacibart braxlosiran (del-brax) met its primary and key…
NVSNovartis AG
Novartis announced that the FORTITUDE Phase I/II study of delpacibart braxlosiran (del-brax) met its primary and key secondary endpoints. The biomarker cohort, involving 51 patients with facioscapulohumeral muscular dystrophy (FSHD), showed reductions in KHDC1L and creatine kinase levels, indicating target engagement and reduced muscle damage. Del-brax is an investigational antibody oligonucleotide conjugate (AOC) acquired through the February 2026 Avidity Biosciences transaction. Following these results, Novartis plans to engage global regulatory authorities regarding the data while its Phase III study continues to enroll 200 patients. Novartis is a pharmaceutical company that develops innovative medicines.